利钠肽：分子生物学、病理生理学及对心脏病专家的临床意义

Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist.

作者信息

D'Alessandro Raffaella, Masarone Daniele, Buono Andrea, Gravino Rita, Rea Alessandra, Salerno Gemma, Golia Enrica, Ammendola Ernesto, Del Giorno Giuseppe, Santangelo Lucio, Russo Maria Giovanna, Calabrò Raffaele, Bossone Eduardo, Pacileo Giuseppe, Limongelli Giuseppe

机构信息

Department of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy.

出版信息

Future Cardiol. 2013 Jul;9(4):519-34. doi: 10.2217/fca.13.32.

DOI:10.2217/fca.13.32

PMID:23834693

Abstract

Natriuretic peptides (NPs) counter the effects of volume overload or adrenergic activation of the cardiovascular system. They are able to induce arterial vasodilatations, natriuresis and diuresis, and they reduce the activities of the renin-angiotensin-aldosterone system and the sympathetic nervous system. However, in addition to wall stress, other factors have been associated with elevated natriuretic peptide levels. Since 2000, because of their characteristics, NPs have become quantitative plasma biomarkers of heart failure. Nowadays, NPs play an important role not only in the diagnosis of heart failure, but also for a prognostic purpose and a guide to medical therapy. Finally, a new drug that modulates the NP system or recombinant analogs of NPs are now available in patients with heart failure.

摘要

利钠肽（NPs）可对抗容量超负荷或心血管系统肾上腺素能激活的影响。它们能够诱导动脉血管舒张、利钠和利尿，并降低肾素-血管紧张素-醛固酮系统和交感神经系统的活性。然而，除了壁应力外，其他因素也与利钠肽水平升高有关。自2000年以来，由于其特性，NPs已成为心力衰竭的定量血浆生物标志物。如今，NPs不仅在心力衰竭的诊断中发挥重要作用，而且在预后评估和药物治疗指导方面也具有重要意义。最后，一种调节NP系统的新药或NP的重组类似物现已应用于心力衰竭患者。